{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:56:51Z","timestamp":1783353411995,"version":"3.54.6"},"reference-count":13,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate real\u2010world outcomes with rVIII\u2010SingleChain and other commonly used recombinant FVIII (rFVIII) products.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Hemophilia treatment centers in Germany (n\u00a0=\u00a021) contributed patient chart data. Inclusion criteria were prophylactic treatment with one of five rFVIII products for \u22658\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Male patients (n\u00a0=\u00a0225) were included: rVIII\u2010SingleChain (n\u00a0=\u00a040), rFVIIIFc (n\u00a0=\u00a047), octocog alfa (rFVIII; n\u00a0=\u00a058), octocog alfa (BAY 81\u20108973; n\u00a0=\u00a040), or moroctocog alfa (n\u00a0=\u00a040). In patients with severe disease (n\u00a0=\u00a076), 66.6%, 70.0%, 20.0%, 7.7%, and 27.3% were dosed \u22642\u00d7\/week, respectively. Irrespective of dosing frequency, mean annualized bleed rates (ABRs)\/annualized spontaneous bleed rates (AsBRs) were 0.3\/0.1, 0.8\/0.4, 1.1\/0.5, 1.5\/0.8, and 1.4\/0.6, and mean FVIII consumption (IU\/kg\/week) was 83.2, 97.2, 92.5, 104.0, and 102.1, respectively. Results for all patients were similar. Of the patients on prophylaxis with prior therapy and after switching to rVIII\u2010SingleChain (n\u00a0=\u00a021), mean ABR\/AsBRs were 0.7\/0.3 and 0.2\/0.0, respectively. After switching to rVIII\u2010SingleChain, mean FVIII consumption reduced (109.4 vs 74.5\u00a0IU\/kg\/week), and percentage of patients dosed \u22642\u00d7\/week increased (0% to 71.4%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>rVIII\u2010SingleChain prophylaxis provides excellent bleeding protection, with potentially lowest factor consumption among the products assessed. Patients who switched to rVIII\u2010SingleChain prophylaxis reduced dosing frequency and consumption compared with prior treatment, with similar or potentially lower bleeding rates.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13378","type":"journal-article","created":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T17:56:25Z","timestamp":1577555785000},"page":"310-317","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII\u2010SingleChain and other common rFVIII products in Germany"],"prefix":"10.1111","volume":"104","author":[{"given":"Martin","family":"Olivieri","sequence":"first","affiliation":[{"name":"Paediatric Haemophilia Centre Department of Paediatrics Dr. von Hauner Children's Hospital Ludwig\u2010Maximilians\u2010Universit\u00e4t M\u00fcnchen Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sommerer","sequence":"additional","affiliation":[{"name":"CSL Behring Hattersheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Maro","sequence":"additional","affiliation":[{"name":"Adivo Associates San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-3839","authenticated-orcid":false,"given":"Songkai","family":"Yan","sequence":"additional","affiliation":[{"name":"CSL Behring King of Prussia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-528414"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_10_5_1","unstructured":"National Hemophilia Foundation.MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available at:http:\/\/www.hemophilia.org\/NHFWeb\/MainPgs\/MainNHF.aspx?menuxml:id=57&contentxml:id=1007"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S43734"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-687434"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(13)70150-6"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12985"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13647"},{"key":"e_1_2_10_12_1","first-page":"39","article-title":"Real\u2010world analysis of dispensed international units of coagulation factor VIII and resultant expenditures for hemophilia A patients: a comparison between standard half\u2010life and extended half\u2010life products","volume":"27","author":"Chhabra A","year":"2018","journal-title":"Manag Care"},{"key":"e_1_2_10_13_1","unstructured":"Paul Ehrlich Institut.Data on patients with congenital haemostasis disorders.2018; Available at:https:\/\/www.pei.de\/EN\/information\/pharmacists-physicians\/dhr-german-haemophilia-registry\/reports\/dhr-reports-node.html"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712464509"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13378","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T22:43:53Z","timestamp":1694040233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/ejh.13378"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13378","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"assertion":[{"value":"2019-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}